Network leverage DrugDev sits within the IQVIA ecosystem and operates the largest global network of active opted-in investigators, presenting a strong cross-sell opportunity to sponsors and CROs seeking scalable investigator access, site startup acceleration, and streamlined payments.

Unified platform The company offers a cloud-based, unified suite for site selection, startup, investigator payments, and operations, which can be positioned to consolidate multiple clinical trial workflows for sponsors looking to reduce complexity and vendor fragmentation.

Investigator data Access to the Investigator Databank and the TransCelerate Investigator Registry creates a defensible data asset for faster site identification, feasibility, and eligibility checks, enabling faster trial execution and improved enrollment planning.

Strategic partnerships Past and ongoing collaborations with Novartis, CISCRP, SCRS, and SecureConsent indicate a proven track record with large pharma and industry bodies, suggesting upsell opportunities around extended eConsent, patient engagement, and sponsored education solutions.

Growth signals As an IQVIA portfolio company with revenue in the upper mid range and a scalable technology stack on AWS and modern tools, DrugDev is positioned to offer expansion to mid-to-large sponsors seeking robust trial operations automation and international investigator networks.